Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing
- PMID: 9448170
- DOI: 10.1111/j.1572-0241.1998.035_c.x
Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing
Abstract
Objective: One-week triple therapy has been shown to be effective in Helicobacter pylori eradication and duodenal ulcer healing. However, the optimal therapeutic combination has not yet been identified. Bismuth-containing regimens have the advantage of requiring only one antibiotic. It has been suggested that high doses of omeprazole improve the bactericidal efficacy of antimicrobial regimens against H. pylori. We evaluated the efficacy of two 1-wk triple-therapy regimens for H. pylori eradication and duodenal ulcer healing.
Methods: On an intention-to-treat basis, 182 patients with H. pylori-associated duodenal ulcer were randomized. Group OCB patients (n = 91) were given omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and colloidal bismuth subcitrate 120 mg q.i.d. for 7 days. Group OCA patients (n = 91) were treated with omeprazole and clarithromycin at the same doses plus amoxicillin 1 g b.i.d., also for 7 days. Endoscopies were performed at entry and at 4 wk after the end of treatment. The presence of H. pylori was assessed by urease test, histology, Gram stain, and culture. No patient received follow-up treatment.
Results: H. pylori eradication rates achieved in the OCB and OCA groups were similar whether by intention-to-treat (82.4% vs 88.9% ;p = 0.21) or per protocol analysis (83.3% vs 89.9%; p = 0.19). Duodenal ulcer healing rates also were the same for OCB and OCA in intention-to treat (91.2% vs 91.1%) and per protocol analysis (92.2% vs 92.1%), respectively (p = 0.98).
Conclusions: High rates of H. pylori eradication and duodenal ulcer healing were obtained with both short-treatment regimens, which were safe and well-tolerated. Colloidal bismuth subcitrate seems to be a good alternative to amoxicillin in the triple-therapy combination with omeprazole and clarithromycin. The omeprazole dose does not seem to play a major role in H. pylori eradication in these therapeutic combinations.
Similar articles
-
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study.Am J Gastroenterol. 1995 May;90(5):718-21. Am J Gastroenterol. 1995. PMID: 7733075 Clinical Trial.
-
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.Am J Gastroenterol. 1998 Apr;93(4):584-90. doi: 10.1111/j.1572-0241.1998.169_b.x. Am J Gastroenterol. 1998. PMID: 9576452 Clinical Trial.
-
[new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].Med Clin (Barc). 1998 Jan 17;110(1):1-5. Med Clin (Barc). 1998. PMID: 9527978 Clinical Trial. Spanish.
-
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis.Am J Gastroenterol. 1996 Feb;91(2):246-57. Am J Gastroenterol. 1996. PMID: 8607488 Review.
-
Therapy of H. pylori infection.J Physiol Pharmacol. 1997 Sep;48 Suppl 4:39-46. J Physiol Pharmacol. 1997. PMID: 9440054 Review.
Cited by
-
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.World J Gastroenterol. 2004 Mar 1;10(5):668-71. doi: 10.3748/wjg.v10.i5.668. World J Gastroenterol. 2004. PMID: 14991935 Free PMC article. Clinical Trial.
-
Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.Drugs. 1998 Sep;56(3):447-86. doi: 10.2165/00003495-199856030-00012. Drugs. 1998. PMID: 9777317 Review.
-
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.World J Gastroenterol. 2004 Jun 1;10(11):1656-8. doi: 10.3748/wjg.v10.i11.1656. World J Gastroenterol. 2004. PMID: 15162544 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical